Turnstone Biologics Corp (TSBX)

Feb 13, 2025

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne

Feb 13, 2025

Feb 12, 2025

Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN

Feb 12, 2025

Feb 12, 2025

Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada

Feb 12, 2025

Feb 10, 2025

Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks

Feb 10, 2025

Feb 08, 2025

Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World

Feb 08, 2025

Feb 08, 2025

Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Feb 08, 2025

Feb 07, 2025

Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter

Feb 07, 2025

Feb 07, 2025

Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World

Feb 07, 2025

Feb 06, 2025

Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN

Feb 06, 2025

Feb 06, 2025

A Look at Turnstone Biologics Corp (TSBX) Shares in the Recent Past Indicates Growth - SETE News

Feb 06, 2025

Feb 05, 2025

TSBX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Feb 05, 2025

Feb 05, 2025

Turnstone Biologics to explore strategic alternatives - The Pharma Letter

Feb 05, 2025

Feb 05, 2025

Piper Sandler Downgrades Turnstone Biologics to Neutral From Overweight, Adjusts Price Target to $0.40 From $3.75 - Marketscreener.com

Feb 05, 2025

Feb 05, 2025

Turnstone Biologics Corp (NASDAQ: TSBX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel

Feb 05, 2025

Feb 05, 2025

Piper Sandler cuts Turnstone Biologics stock rating to neutral - MSN

Feb 05, 2025

Feb 05, 2025

Turnstone Biologics halts TIDAL-01 development, seeks alternatives By Investing.com - Investing.com South Africa

Feb 05, 2025

Feb 04, 2025

TSBX’s price-to-book ratio: An indicator of the company’s performance - US Post News

Feb 04, 2025

Feb 04, 2025

Turnstone Biologics Stops Tidal-01 Trials, Explores Strategic Alternatives; Shares Rise - Marketscreener.com

Feb 04, 2025

Feb 04, 2025

Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes - TipRanks

Feb 04, 2025

Feb 04, 2025

Turnstone Biologics Announces Plans to Explore Strategic Alternatives - The Manila Times

Feb 04, 2025

Feb 04, 2025

Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review - Nasdaq

Feb 04, 2025

Jan 29, 2025

Scailyte Announces Collaboration With Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors With TIL Therapy - ACCESS Newswire

Jan 29, 2025

Jan 18, 2025

Head to Head Survey: Turnstone Biologics (NASDAQ:TSBX) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World

Jan 18, 2025

Jan 12, 2025

Reviewing AlloVir (NASDAQ:ALVR) and Turnstone Biologics (NASDAQ:TSBX) - Defense World

Jan 12, 2025

Jan 09, 2025

Turnstone Biologics (NASDAQ:TSBX) Stock Price Down 9.1% – Time to Sell? - Defense World

Jan 09, 2025

Dec 18, 2024

Fmr LLC Boosts Stock Position in Turnstone Biologics Corp. (NASDAQ:TSBX) - Defense World

Dec 18, 2024

Dec 05, 2024

Turnstone Biologics stock plunges to 52-week low of $0.44 By Investing.com - Investing.com Australia

Dec 05, 2024

Dec 05, 2024

Turnstone Biologics stock plunges to 52-week low of $0.44 - Investing.com

Dec 05, 2024

Nov 23, 2024

Turnstone Biologics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 23, 2024

Nov 15, 2024

Turnstone Biologics stock downgraded amid concerns over therapy scalability and funding - Investing.com

Nov 15, 2024

Nov 13, 2024

Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - The Manila Times

Nov 13, 2024

Nov 12, 2024

Turnstone Biologics Faces Financial and Operational Challenges - TipRanks

Nov 12, 2024

Nov 12, 2024

Turnstone Biologics Reports 25% Response Rate in Cancer Trial, Extends Cash Runway to 2026 | TSBX Stock News - StockTitan

Nov 12, 2024

Nov 06, 2024

Turnstone advances TIL therapy for solid tumors at SITC meeting By Investing.com - Investing.com Australia

Nov 06, 2024

Nov 05, 2024

Turnstone advances TIL therapy for solid tumors at SITC meeting - Investing.com

Nov 05, 2024

Nov 05, 2024

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times

Nov 05, 2024

Nov 05, 2024

Turnstone Biologics Reveals Breakthrough TIL Cancer Treatment Data at SITC 2024 | TSBX Stock News - StockTitan

Nov 05, 2024

Nov 02, 2024

Warning: TSBX is at high risk of performing badly - MSN

Nov 02, 2024

Oct 16, 2024

Turnstone Biologics (NASDAQ:TSBX) & Recursion Pharmaceuticals (NASDAQ:RXRX) Critical Contrast - Defense World

Oct 16, 2024

Oct 14, 2024

BofA downgrades Turnstone stock, citing wait-and-see approach until 2025 data - Investing.com

Oct 14, 2024

Oct 14, 2024

Turnstone fires most staff in bid to to extend runway - The Pharma Letter

Oct 14, 2024

Oct 12, 2024

Turnstone Biologics Streamlines Operations and Leadership - Yahoo Finance

Oct 12, 2024

Oct 12, 2024

Turnstone Biologics announces strategic cuts and focus shift - Investing.com

Oct 12, 2024

Oct 11, 2024

Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway - ForexTV.com

Oct 11, 2024

Oct 11, 2024

Turnstone lays off 60% of staff, shakes up C-suite to keep cancer cell therapy on track - Fierce Biotech

Oct 11, 2024

Oct 10, 2024

Turnstone Biologics stock plunges to 52-week low of $0.45 - Investing.com

Oct 10, 2024